Mainz Biomed Stock Scheduled to Reverse Split on Tuesday, December 3rd (NASDAQ:MYNZ)

Mainz Biomed (NASDAQ:MYNZ)’s stock is set to reverse split before the market opens on Tuesday, December 3rd. The 1-40 reverse split was announced on Friday, November 29th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, December 2nd.

Mainz Biomed Stock Down 14.1 %

MYNZ stock traded down $0.04 on Friday, reaching $0.22. 7,094,717 shares of the company traded hands, compared to its average volume of 1,350,238. Mainz Biomed has a one year low of $0.19 and a one year high of $1.79. The firm has a fifty day simple moving average of $0.26 and a 200-day simple moving average of $0.39.

Analyst Ratings Changes

Separately, HC Wainwright lowered Mainz Biomed from a “buy” rating to a “neutral” rating in a research report on Monday.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.